CA AB3095

Requires licensed health care practitioners performing unapproved FDA stem cell therapies to include in all print and digital advertising materials, including websites, that the therapies are not FDA approved.

Maintains existing requirements for practitioners to display prominent notices (at least 8.5" x 11" in 40-point type) in their offices and provide written notice to patients prior to initial stem cell therapy.

Exempts health care practitioners who have obtained FDA approval or clearance for investigational new drugs or investigational device exemptions from these requirements.

Exempts research conducted under the California Stem Cell Research and Cures Act from these notification and advertising requirements.

Authorizes licensing boards to cite and fine practitioners up to $1,000 per violation, with no citation for first violations but fines allowed for second and subsequent violations.